How CAR-T works, which diagnoses it applies to, and an honest account of costs and risks.
23.08.2026
CAR-T cell therapy attracts attention because the mechanism sounds like science fiction and because it has produced durable remissions in patients who had run out of options. Both are true. What is also true is that it applies to a specific and fairly narrow group of diagnoses, carries serious risks of its own, and costs more than almost anything else in oncology.
Your own T-cells are collected from the blood in a procedure called leukapheresis, similar to a long blood donation. The cells are shipped to a manufacturing facility, where they are genetically modified to express a chimeric antigen receptor — a synthetic receptor that recognises a protein on your cancer cells. The modified cells are multiplied, quality-tested and shipped back.
Before infusion you receive lymphodepleting chemotherapy, which clears space in the immune system for the new cells. Then the cells are infused, and they multiply inside you and attack the target. Because they persist, the effect can continue for years rather than ending when a drug is cleared.
The approved products target B-cell malignancies. Axicabtagene ciloleucel — Yescarta — is used in diffuse large B-cell lymphoma and follicular lymphoma. Tisagenlecleucel — Kymriah — is used in acute lymphoblastic leukaemia and DLBCL. Other products target multiple myeloma, and work continues on further indications.
The pattern is important: these are relapsed or refractory cases, patients who have already been through standard treatment and either did not respond or relapsed. CAR-T is not a first-line option, and it does not currently apply to solid tumours outside trials. If someone offers you CAR-T for a solid tumour outside a registered clinical trial, be sceptical.
Roughly four to six weeks from collection to being clear of the intensive monitoring period. Leukapheresis takes a day. Manufacturing takes two to four weeks, and this is the interval nobody can compress — the cells are being grown. Bridging therapy is often given during the wait to keep the disease controlled. Lymphodepletion runs a few days, the infusion itself takes under an hour, and then comes intensive monitoring.
Plan to stay near the treating centre for the whole period. This is not a treatment you fly home in the middle of.
Published figures for Istanbul put CAR-T at roughly 80,000–150,000 $ depending on the product and indication. That typically covers leukapheresis, manufacturing, lymphodepleting chemotherapy, the infusion and four to six weeks of monitoring.
The manufacturing is most of the cost. These are individually produced biological products — your cells, engineered for you — and the price reflects a manufacturing process that cannot be batched. What may sit outside a quote: intensive care if severe toxicity occurs, extended admission, and treatment of complications.
Cytokine release syndrome is the main one — a systemic inflammatory response as the engineered cells activate. It ranges from fever and low blood pressure to a critical illness requiring intensive care, and it is managed with specific drugs including tocilizumab. Neurological toxicity, known as ICANS, can cause confusion, difficulty speaking, tremor and in severe cases seizures; it is usually reversible but frightening to witness.
Prolonged low blood counts and susceptibility to infection follow, sometimes for months, because the therapy depletes normal B-cells along with malignant ones. This is why CAR-T is delivered only in centres with intensive care capability and staff trained specifically to recognise these syndromes early.
Ask how many CAR-T patients the centre has treated and over what period. Ask which specific product they use — an approved, named product, not a description. Ask what their intensive care arrangements are and whether tocilizumab is held on site. Ask who follows you after the monitoring period ends.
A centre that answers these directly is a centre that does this regularly. Vagueness on any of them is a reason to look elsewhere.
Can CAR-T treat solid tumours?
Not currently outside clinical trials. Approved products target B-cell blood cancers and multiple myeloma. Research on solid tumours is active but not established practice.
Is it a one-time treatment?
The infusion is given once, and the engineered cells can persist and continue working for years. It is not a guarantee of cure, and relapse after CAR-T does occur.
What do you need to assess eligibility?
The full haematology record, current disease status, all previous treatment lines with drug names and responses, recent imaging, and bone marrow biopsy results.
Related reading
Lymphoma and Leukaemia in Adults: What Comes After a Relapse
Bone Marrow Transplant in Turkey: Types, Timelines and What It Costs
Getting a Second Opinion on a Cancer Diagnosis from Another Country
This page is general information, not medical advice. Eligibility for cellular therapy, its risks and expected outcomes are determined individually by a licensed haematologist at a certified centre.
Send us what you already have — the pathology report, imaging on disc, discharge summaries. A specialist at a partner hospital will review it and tell you what is realistic in your case and how quickly treatment could begin. Reviewing your documents costs nothing and commits you to nothing.
Send your documents
Hospital group, standalone clinic, licensed facilitator or an uncertified broker: whoever issues your invoice is who answers when something goes wrong. How to tell them apart.
Turkey's Ministry of Health publishes the list of clinics allowed to treat foreign patients. How to check a clinic against it, plus JCI, TUSKA accreditation and the surgeon.
A realistic day-by-day recovery timeline after flap-free SMILE laser eye surgery in Turkey, from the blurry first evening to fully settled vision.
